Erratum: A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice (Human Molecular Genetics (2009) 18:22 (4405-4414) DOI: 10.1093/hmg/ddp395);A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice

Human Molecular Genetics

Volumn 18, Issue 22, 2009, Pages 4405-4414

  Yin, Haifang ^a,b   Moulton, Hong M ^b   Betts, Corinne ^a   Seow, Yiqi ^a   Boutilier, Jordan ^c   Iverson, Patrick L ^c   Wood, Matthew J A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c AVI BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; B PEPTIDE MUSCLE SPECIFIC HEPTAPEPTIDE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER FUSION PEPTIDE; B PEPTIDE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER FUSION PEPTIDE; CHIMERIC PROTEIN; CREATINE KINASE; DYSTROPHIN; DYSTROPHIN ASSOCIATED PROTEIN COMPLEX; HYBRID PROTEIN; MUSCLE SPECIFIC HEPTAPEPTIDE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER FUSION PEPTIDE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DYSTROPHY; EXON; GRIP STRENGTH; LOW DRUG DOSE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SINGLE DRUG DOSE; SKELETAL MUSCLE;

ANIMALIA; MUS;

EID: 70350697818     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddy377     Document Type: Erratum

References (27)

1. Hoffman, E.P., Brown, R.H. and Kunkel, L.M. (1987) Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell, 51, 919-928.
2. Aartsma-Rus, A., Kaman, W.E., Weij, R., den Dunnen, J.T., van Ommen, G.J. and van Deutekom, J.C. (2006) Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol. Ther., 14, 401-407.
3. Alter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S.D., Partridge, T.A. and Lu, Q.L. (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med., 12, 175-177.
4. Gebski, B.L., Mann, C.J., Fletcher, S. and Wilton, S.D. (2003) Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum. Mol. Genet., 12, 1801-1811.
5. Aartsma-Rus, A., Janson, A.A., Kaman, W.E., Bremmer-Bout, M., den Dunnen, J.T., Baas, F., van Ommen, G.J. and van Deutekom, J.C. (2003) Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum. Mol. Genet., 12, 907-914.
6. Aartsma-Rus, A., Janson, A.A., Kaman, W.E., Bremmer-Bout, M., van Ommen, G.J., den Dunnen, J.T. and van Deutekom, J.C. (2004) Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am. J. Hum. Genet., 74, 83-92.
7. Lu, Q.L., Mann, C.J., Lou, F., Bou-Gharios, G., Morris, G.E., Xue, S.A., Fletcher, S., Partridge, T.A. and Wilton, S.D. (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med., 9, 1009-1014.
8. Lu, Q.L., Rabinowitz, A., Chen, Y.C., Yokota, T., Yin, H., Alter, J., Jadoon, A., Bou-Gharios, G. and Partridge, T. (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl Acad. Sci. USA, 102, 198-203.
9. Mann, C.J., Honeyman, K., Cheng, A.J., Ly, T., Lloyd, F., Fletcher, S., Morgan, J.E., Partridge, T.A. and Wilton, S.D. (2001) Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl Acad. Sci. USA, 98, 42-47.
10. van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., Frankhuizen, W.S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J.T., Koop, K., van der Kooi, A.J., Goemans, N.M. et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357, 2677-2686.
11. Wilton, S.D., Fall, A.M., Harding, P.L., McClorey, G., Coleman, C. and Fletcher, S. (2007) Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol. Ther., 15, 1288-1296.
12. Yin, H., Lu, Q. and Wood, M. (2008) Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol. Ther., 16, 38-45.
13. England, S.B., Nicholson, L.V., Johnson, M.A., Forrest, S.M., Love, D.R., Zubrzycka-Gaarn, E.E., Bulman, D.E., Harris, J.B. and Davies, K.E. (1990) Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature, 343, 180-182.
14. Gregorevic, P., Blankinship, M.J., Allen, J.M., Crawford, R.W., Meuse, L., Miller, D.G., Russell, D.W. and Chamberlain, J.S. (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med., 10, 828-834.
15. Jearawiriyapaisarn, N., Moulton, H.M., Buckley, B., Roberts, J., Sazani, P., Fucharoen, S., Iversen, P.L. and Kole, R. (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol. Ther., 16, 1624-1629.
16. Yin, H., Moulton, H.M., Seow, Y., Boyd, C., Boutilier, J., Iverson, P. and Wood, M. (2008) Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum. Mol. Genet., 17, 3909-3918.
17. Wu, B., Li, Y., Morcos, P.A., Doran, T.J., Lu, P. and Lu, Q.L. (2009) Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol. Ther., 17, 864-871.
18. Wu, B., Moulton, H.M., Iversen, P.L., Jiang, J., Li, J., Li, J., Spurney, C.F., Sali, A., Guerron, A.D., Nagaraju, K. et al. (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc. Natl Acad. Sci. USA, 105, 14814-14819.
19. Kumar, P., Wu, H., McBride, J.L., Jung, K.E., Kim, M.H., Davidson, B.L., Lee, S.K., Shankar, P. and Manjunath, N. (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature, 448, 39-43.
20. Samoylova, T.I. and Smith, B.F. (1999) Elucidation of muscle-binding peptides by phage display screening. Muscle Nerve, 22, 460-466.
21. Blake, D.J., Weir, A., Newey, S.E. and Davies, K.E. (2002) Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev., 82, 291-329.
22. Tinsley, J.M., Blake, D.J., Zuellig, R.A. and Davies, K.E. (1994) Increasing complexity of the dystrophin-associated protein complex. Proc. Natl Acad. Sci. USA, 91, 8307-8313.
23. Fowler, S.C., Zarcone, T.J., Chen, R., Taylor, M.D. and Wright, D.E. (2002) Low grip strength, impaired tongue force and hyperactivity induced by overexpression of neurotrophin-3 in mouse skeletal muscle. Int. J. Dev. Neurosci., 20, 303-308.
24. Qiao, C., Li, J., Jiang, J., Zhu, X., Wang, B., Li, J. and Xiao, X. (2008) Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum. Gene. Ther., 19, 241-254.
25. Glesby, M.J., Rosenmann, E., Nylen, E.G. and Wrogemann, K. (1988) Serum CK, calcium, magnesium, and oxidative phosphorylation in mdx mouse muscular dystrophy. Muscle Nerve, 11, 852-856.
26. Wells, D.J., Wells, K.E., Walsh, F.S., Davies, K.E., Goldspink, G., Love, D.R., ChanThomas, P., Dunckley, M.G., Piper, T. and Dickson, G. (1992) Human dystrophin expression corrects the myopathic phenotype in transgenic mdx mice. Hum. Mol. Genet., 1, 35-40.
27. Wu, R.P., Youngblood, D.S., Hassinger, J.N., Lovejoy, C.E., Nelson, M.H., Iversen, P.L. and Moulton, H.M. (2007) Cell-penetrating peptides as transporters for morpholino oligomers: Effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acid. Res., 35, 5182-5191.